N B Roberts and colleagues 1 reported that the renal excretion rates of noradrenaline and dopamine, but not adrenaline, were lower in patients with lower creatinine clearances. Measurements were made on 24-h urine collections from 50 patients with chronic renal failure, and the authors' conclusions were based on the presence or absence of statistically signi®cant linear regressions between excretion rate and creatinine clearance.
N B Roberts and colleagues 1 reported that the renal excretion rates of noradrenaline and dopamine, but not adrenaline, were lower in patients with lower creatinine clearances. Measurements were made on 24-h urine collections from 50 patients with chronic renal failure, and the authors' conclusions were based on the presence or absence of statistically signi®cant linear regressions between excretion rate and creatinine clearance.
However, both excretion rate and clearance contain the same variable ± 24-h urine volume. Excretion rate is concentration multiplied by timed volume and creatinine clearance is the ratio of urine to plasma creatinine concentration multiplied by timed volume. Thus, a statistically signi®cant positive regression could be obtained in the absence of a true relationship if the 24-h urines included over-and under-collections. These are very common even in well-instructed renal patients; 2 an accurately timed collection of urine is incredibly dif®cult to obtain. 3 It is the absence of a signi®cant regression for adrenaline that makes this explanation less likely.
The apparent dependence of excretion rates on creatinine clearance could be con®rmed or refuted by examination of the regression of the catecholamine concentrations on the ratios of urine to plasma creatinine concentrations, so omitting the common (and unreliable) variable, 24-h urine volume. The letter of R B Payne raises some interesting questions. The main point about our data was that urinary noradrenaline and dopamine fell with decreasing creatinine clearance (GFR) whereas adrenaline did not. This implies that adrenaline is either produced by the body differently in renal disease or is treated differently by the failing kidney. It is therefore unnecessary to invoke the inaccuracy of 24-h urine collection to explain the difference between the correlations. In any event, our patients form a well-schooled population in whom the reproducibility of creatinine clearances is good, with a precision of 12´0% coef®cient of variation or better, as shown by the relatively small scatter around the regression lines of ®gs 1(a) and 1(c) in our article.
R B PAYNE
1 Additionally, such a false correlation could not explain the relationships observed over such a wide range of renal function. The alternative suggestion, that urine/plasma creatinine ratios are compared to catecholamine concentrations, is fraught with problems. In patients with normal renal function or mild renal impairment, a false correlation between the urinary concentration of creatinine and catecholamines could arise from random variations in the dilution, dependent on the state of hydration. Also, in patients with renal impairment, urinary excretion of creatinine is reduced due to extra renal metabolism and changes in muscle mass.
Undoubtedly, 24-h urine collections can be inaccurate but can still provide useful information about the ef®ciency of renal glomerular ®ltration and the outputs of urine catecholamines, as in our study. 
External quality assurance ± a personal view
Following publication of the personal vieẁ External quality assurance' 1 and the ensuing comments from scheme organizers 2±6 in the Letters section of the Annals, I would like to add a few points from the perspective of a participant in the schemes.
Most scheme participants rely heavily on the data obtained from the schemes for an independent assessment of assay performance within their laboratories. External results are used for quality assurance (QA) of internal quality assessment procedures. It is important that the material used results in reliable information. Doug Hirst appears to disapprove of the formation of`sub-groups' for different methodology on two grounds. Firstly, it encourages toleration of analytically inadequate instrumentation and/or calibration. Secondly, it permits manufacturers to claim that external quality assurance (EQA) deviation is due solely to matrix effects.
Matrix effects observed with QA material but not with fresh human serum have been suggested to indicate lack of speci®city (reduced analytical accuracy) for an analyte. 7 This is likely for inorganic analytes. For other analytes, such as enzymes and proteins, it is very dif®cult if not impossible to achieve levels required for EQA with added material, which will exactly replicate the behaviour of the analyte under normal laboratory assay conditions. Apparent poor performance for these analytes in an external scheme may well be a characteristic of the QA material. Unexpectedly high coef®cients of variation (CVs) or increased differences in method means should be a warning that there may be a problem with the material in particular circumstances. In such situations, subgroup data can be useful and are justi®ed.
During the last year, the laboratory generated spuriously low creatine kinase (CK) results in our external QA despite satisfactory internal QA. The presence of an intermittent instrument fault was unlikely. Patient samples were run in duplicate as a precaution, but outliers never appeared with patient samples. It became apparent that external QA`blunders' occurred when certain lot numbers of National External Quality Assurance Scheme (NEQAS) material were reissued. This was associated with an increase in between-lab CV on EQA returns for these lots.
The problem was related to increased photolability of QA material CK compared with human serum CK.
Comparison of a new bottle of`problem batch' material with fresh human serum showed marked photolability. The external scheme material fell to 30% of its original activity within 2 h in natural light (not direct sunlight). Unfrozen patient serum treated similarly was not affected.
The matter was compounded by our practice of transferring portions of reconstituted material into transparent LP4 tubes from the brown primary container to allow CK measurement on three instruments, one of which was near the window. Since protecting the NEQAS material from light, no further problems have been experienced. This is an example of what may happen if one assumes QA material will behave in the same way as human serum. Investigation of apparent poor performance can be very costly in terms of time and reagents. Participants in the schemes need to understand that QA materials may be more`fragile' than fresh human serum and warnings need higher pro®le than those given in small print on a package insert. Some enzymes may need rapid analysis, some need to`mature'. The different behaviour of batches of QA material needs to be characterized before distribution, and participants should be made more aware of the limitations of these products. 
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